Does taking HIV medicine 52 times a year work as well as 365?
Yes. In a phase 3 trial of 607 adults, a weekly HIV pill held the virus down in 93.4 percent of people at 48 weeks, compared with 92.4 percent of people who stayed on the standard daily pill. Not one person on the weekly pill had the virus climb back to a detectable level.
Modern HIV treatment already works well. A single daily tablet can push the amount of virus in the blood so low that standard tests cannot find it, which is what doctors mean by “virally suppressed.” The problem is not the medicine, it is the calendar. Taking a pill every single day, for decades, is hard for a lot of people, and the trial authors write that “challenges to adherence continue to limit effective treatment.”
This trial tested a different rhythm. Researchers combined two drugs, islatravir and lenacapavir, into one tablet taken once a week. They compared it against bictegravir, emtricitabine, and tenofovir alafenamide, the three-drug daily tablet that many people with HIV already take. Everyone in the study was doing well on the daily pill before they switched.
What the data show
At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher, meaning the virus had become detectable again, showed up in zero people on the weekly pill and 1 person out of 303 on the daily pill. That is a difference of 0.3 percentage points in favor of the weekly pill, and the true difference is very likely somewhere between 1.4 points better and 0.8 points worse for it. This was the main question the trial was built to answer, and the researchers had agreed in advance that the weekly pill could fall behind by as much as 4 percentage points and still count as good enough. It never came close to that line.
Full suppression, a viral level under 50 copies per milliliter, was reported in 284 people (93.4 percent) on the weekly pill and 280 people (92.4 percent) on the daily pill. The weekly pill came out 1.0 percentage point ahead, and the true gap is very likely somewhere between 3.2 points behind and 5.2 points ahead. In plain terms, the two regimens performed the same.
The immune system held steady too. CD4+ T cells, the white blood cells HIV attacks, drifted down by an average of 10 cells per microliter on the weekly pill and 18 cells per microliter on the daily pill. Those small dips are the kind of normal fluctuation you see in people who are already stable.
Dr. Kumar’s Take
This is a practical result rather than a flashy one, and that is exactly why I like it. Nobody in this trial got healthier. They took 52 doses a year instead of 365, and nothing bad happened. Dropping from a daily decision to a weekly one is the whole point, and the authors are direct about why they went looking for it: adherence problems keep getting in the way of treatment that otherwise works.
I want to be careful about one thing, though. Everyone here was already suppressed on a daily pill for at least 6 months. These are people whose HIV was under good control and who had shown they could take medicine reliably. That is the easiest possible group to switch. This trial tells us the weekly pill can hold a stable patient stable. It does not tell us how it performs in someone starting treatment for the first time, or in someone whose adherence has been shaky, which is the group the weekly schedule is arguably designed for.
How the trial was done
This was a phase 3, double-blind, randomized, active-controlled, noninferiority trial run across 12 countries. Double-blind means neither the participants nor their doctors knew which regimen anyone was on, and to keep it that way, everyone took a matching dummy pill for the schedule they were not assigned to. Noninferiority means the goal was not to prove the weekly pill was better, only to prove it was not meaningfully worse.
A total of 607 adults were randomly assigned in equal numbers, 304 to weekly islatravir and lenacapavir at 2 mg and 300 mg, and 303 to the daily three-drug tablet, with the trial running for 96 weeks and the main measurement taken at week 48. The group was reasonably mixed: 21 percent were women, 31 percent were Black, 26 percent were Hispanic or Latine, and 15 percent were 65 years of age or older.
Safety, limits, and caveats
Side effects behaved similarly on both schedules. Six people (2.0 percent) on the weekly pill and five (1.7 percent) on the daily pill stopped their assigned regimen because of a side effect. Serious adverse events happened in 16 people (5.3 percent) on the weekly pill and 14 (4.6 percent) on the daily pill. Those gaps are small enough to be chance in a trial this size.
The honest limits are about scope, not safety. Forty-eight weeks is a solid look but it is not a lifetime, and the trial is still running to week 96. Everyone entered already suppressed and already tolerating a specific daily regimen, so the findings apply to switching, not to starting. And the trial was funded by Gilead Sciences and Merck Sharp and Dohme, the two companies that make these drugs, which is standard for a registration trial but always worth knowing.
Practical Takeaways
- If you are living with HIV and doing well on a daily single-tablet regimen, this trial is a reason to ask your HIV specialist about weekly dosing, not a reason to change anything on your own.
- Do not stop or space out your current medicine to imitate a weekly schedule, because the drugs in a daily tablet are not built to last a week and skipping doses is how resistance develops.
- Keep in mind that this evidence applies to people whose virus has been undetectable for at least 6 months, so getting to stable suppression on your current regimen comes first.
- Ask specifically about the 96-week results when they arrive, since the longer data will say more about how durable weekly dosing is.
Related Studies and Research
- Single-dose psilocybin vs placebo: first double-blind depression trial
- A daily pill nearly doubled survival in advanced pancreatic cancer
- New daily diabetes pill beats semaglutide on sugar and weight
- Antidepressant efficacy of Sudarshan Kriya Yoga in melancholia compared with ECT and imipramine
FAQs
Would a weekly HIV pill work for someone just starting treatment?
This trial cannot answer that. Every participant had HIV that was already virologically suppressed for at least 6 months while taking a specific daily three-drug tablet, so the study was a switch study from start to finish. Starting treatment is a different medical situation, because the virus is actively replicating and the body has to be brought under control rather than kept there. Those trials have to be run separately, and until they are, the weekly regimen is evidence-backed only as a switch for people who are already stable.
Does a weekly pill hurt the immune system compared with daily dosing?
The CD4+ T-cell counts say no. Over 48 weeks, average counts moved down by 10 cells per microliter on the weekly regimen and 18 cells per microliter on the daily regimen. The difference between the two groups was 12 cells per microliter in favor of the weekly pill, and the range around that estimate runs from 16 cells worse to 39 cells better, which is a fancy way of saying the two look the same. CD4 counts naturally wobble by more than this from one blood draw to the next in a healthy, suppressed person.
Why does a 48-week result matter if the trial runs 96 weeks?
Forty-eight weeks is the standard checkpoint in HIV drug trials, long enough for a regimen that is failing to show it. If a weekly schedule left the drug levels too low between doses, you would expect the virus to start slipping back within that first year, and here it did not slip back in a single person. The 96-week data still matters, because durability over years is the real question with a lifelong medicine, and rare side effects need time to appear. Treat the 48-week result as strong early evidence rather than the final word.
How much less medicine is this, really?
The change is in how often, not in how strong. A once-weekly tablet means 52 dosing days a year instead of 365, so it removes more than 300 chances to forget, to be away from your medicine, or to have someone notice you taking it. For a treatment that continues for decades, that reduction in daily logistics is the entire point of the drug, since the trial showed no advantage in how well the virus was controlled.
Bottom Line
A once-weekly oral tablet combining islatravir and lenacapavir kept HIV just as well controlled as the standard once-daily three-drug pill over 48 weeks, with 93.4 percent versus 92.4 percent of participants staying virally suppressed and zero versus one person seeing the virus become detectable again. Side effects and serious adverse events were similar. The authors concluded that among people with virologically suppressed HIV-1, once-weekly treatment was noninferior to once-daily treatment. For people already stable on therapy, this points toward a future where HIV is managed 52 times a year instead of every single morning.
